326 related articles for article (PubMed ID: 34180096)
1. Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan.
Yokoyama S; Asano T; Nagano K; Tsuchiya H; Takagishi M; Tsujioka S; Miura N; Matsumoto T
J Gastroenterol Hepatol; 2021 Nov; 36(11):3069-3076. PubMed ID: 34180096
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Ustekinumab for Crohn's Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed.
Nagano K; Hata E; Asano T; Tsuchiya H; Takagishi M; Yamazaki H; Tominaga S; Matsumoto T
Crohns Colitis 360; 2023 Jan; 5(1):otad001. PubMed ID: 36777365
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
5. Safety and Effectiveness of Ustekinumab for Crohn's Disease With Perianal Manifestations: Ad hoc Analysis Data From 1-Year Post-Marketing Surveillance Study in Japan.
Nagano K; Tsuchiya H; Asano T; Yamazaki H; Tominaga S; Matsumoto T
Crohns Colitis 360; 2024 Apr; 6(2):otae035. PubMed ID: 38827168
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
[TBL] [Abstract][Full Text] [Related]
8. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
Thomas PWA; van Caem M; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F;
Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):261-269. PubMed ID: 36708296
[TBL] [Abstract][Full Text] [Related]
9. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.
Plevris N; Fulforth J; Siakavellas S; Robertson A; Hall R; Tyler A; Jenkinson PW; Campbell I; Chuah CS; Kane C; Veryan J; Lam WL; Saunders J; Kelly C; Gaya D; Jafferbhoy H; Macdonald JC; Seenan JP; Mowat C; Naismith G; Potts LF; Sutherland DI; Watts D; Arnott I; Bain G; Jones G; Lees CW
J Gastroenterol Hepatol; 2021 Aug; 36(8):2067-2075. PubMed ID: 33381875
[TBL] [Abstract][Full Text] [Related]
12. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease.
Okuda H; Hosomi S; Itani S; Kurimoto N; Kobayashi Y; Nakata R; Nishida Y; Ominami M; Nadatani Y; Fukunaga S; Otani K; Kamata N; Tanaka F; Nagami Y; Taira K; Ohfuji S; Fujiwara Y
J Gastroenterol Hepatol; 2023 Jun; 38(6):910-920. PubMed ID: 36807301
[TBL] [Abstract][Full Text] [Related]
19. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
